Forbes June 5, 2024
Robert Hart

Topline

Shares for companies focused on psychedelic medicines plummeted during premarket trading on Wednesday after independent experts advised the Food and Drug Administration against approving psychedelic and stimulant drug MDMA, commonly known as ecstacy or molly, for post-traumatic stress disorder, a major setback for those hoping to open a new era of medicine for the often-outlawed substances.

Key Facts

Key Background

Psychedelics are a broad class of drugs that can alter mood, thoughts and perception. Many drugs in the category, which includes substances like MDMA, LSD and psilocybin — the active compound in “magic mushrooms” — are deemed illegal in many parts of the world, though they are increasingly viewed by experts as potentially promising treatments for an array of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider
Measuring Progress for Life Sciences: Trust, Patient Access, and Prevention at a Fork in the Road of Public Health
2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies
Christophe Weber, veteran Takeda CEO, to retire next year
Walmart To Expand Same-Day Prescription Delivery Nationwide
Podcast: Market Failures, Lessons or Opportunities? 1/30/25

Share This Article